share_log

Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target

Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target

Stifel将Orchard Therapeutics的评级下调至持有,宣布目标价为16美元
Benzinga ·  2023/10/05 10:36

Stifel analyst Dae Gon Ha downgrades Orchard Therapeutics (NASDAQ:ORTX) from Buy to Hold and announces $16 price target.

Stifel分析师Dae Gon Ha将Orchard Therapeutics(纳斯达克股票代码:ORTX)的评级从买入下调至持有,并宣布了16美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发